While the involvement of CD8 tissue-resident memory T (TRM) cells in the response to ICB therapy has been reported, less is known about the relevance of CD4 TRM cells. Here, using mouse cancer models and human melanoma samples and NSCLC dataset, the authors show that CD49a+ CD4 TRM cells often accumulate in pre-treatment tumours, and their presence correlates with a favourable response to anti-CTLA-4 therapy.
- Isabelle Damei
- Aziza Caidi
- Fathia Mami-Chouaib
